Drug Trial Radar · NCT06845852
A Phase 1 Mass Balance Study of Varegacestat
Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Feb 25, 2025
Primary completion
Mar 11, 2025
Study completion Mar 26, 2025
Sponsor
- Lead sponsor
- Immunome, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical study is designed to study the mass balance of a single dose of varegacestat in healthy male participants.
Conditions
- Healthy Volunteer
Interventions
varegacestatDrug
Single oral dose of varegacestat
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mass balance of varegacestat following administration of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants.Time frame: Up to 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Frontage Laboratories, Inc.
Secaucus, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.